Ighodaro Osasenaga Mcdonald, Akinloye Oluseyi Adeboye, Ugbaja Regina Ngozi, Omotainse Samuel Olatunbosun
Department of Biochemistry, Faculty of Sciences, Lead City University, Ibadan, Nigeria.
Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta (FUNAAB), Abeokuta, Nigeria.
Int Sch Res Notices. 2017 Jun 7;2017:6463139. doi: 10.1155/2017/6463139. eCollection 2017.
Dyslipidemia is a common metabolic disorder especially in diabetes mellitus (DM). In this study, the ability of (SE) leaf extract to restore lipid homeostasis in streptozotocin-induced diabetes was examined. DM was induced in experimental rats (Wistar strains) using single intraperitoneal dose (55 mg/kg body weight {BW}) of streptozotocin (STZ). Treatment of diabetic rats with SE was oral (p.o), at doses of 400 and 800 mg kg BW, twice daily at 8 h interval for 21 days. Lipid parameters were analyzed in the serum of rats using test kits. SE caused a significant ( ≤ 0.05) reduction in STZ-induced hypercholesterolemia in a dose dependent pattern (13.7 and 17.89%). These effects were comparable to that provided by metformin (15.45%), a standard antidiabetic drug. Similar pattern was noted with serum triglycerides (TG) (10.63 and 19.06%) and LDL (31.47 and 25.97%). Adipose tissue TG level was improved to near normal. Besides, the cardiovascular risk predictors in terms of atherogenic index of plasma (AIP) and LDL/HDL ratio were lowered by 57.85 and 44.12%, respectively. However, the extract failed to significantly reverse the STZ-induced decline in serum HDL. Overall, with AIP value of 0.28 and LDL/HDL ratio of 0.91, SE demonstrated the potential to maintain lipid homeostasis in the diabetics.
血脂异常是一种常见的代谢紊乱，尤其是在糖尿病（DM）中。在本研究中，检测了（SE）叶提取物恢复链脲佐菌素诱导的糖尿病中脂质稳态的能力。使用单次腹腔注射剂量（55mg/kg体重{BW}）的链脲佐菌素（STZ）在实验大鼠（Wistar品系）中诱导糖尿病。用SE对糖尿病大鼠进行口服（p.o）治疗，剂量为400和800mg/kg BW，每天两次，间隔8小时，持续21天。使用测试试剂盒分析大鼠血清中的脂质参数。SE以剂量依赖性模式（13.7%和17.89%）使STZ诱导的高胆固醇血症显著降低（≤0.05）。这些作用与标准抗糖尿病药物二甲双胍（15.45%）提供的作用相当。血清甘油三酯（TG）（10.63%和19.06%）和低密度脂蛋白（LDL）（31.47%和25.97%）也呈现类似模式。脂肪组织TG水平改善至接近正常。此外，血浆动脉粥样硬化指数（AIP）和LDL/HDL比值方面的心血管风险预测指标分别降低了57.85%和44.12%。然而，该提取物未能显著逆转STZ诱导的血清高密度脂蛋白（HDL）下降。总体而言，SE的AIP值为0.28，LDL/HDL比值为0.91，显示出维持糖尿病患者脂质稳态的潜力。
